Program
efgartigimod alfa
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “Efgartigimod IV”.
Its studies are mostly in Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Pemphigus · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Graves Disease, led by argenx.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 4817 open or running | phase 4since Oct 7, 2024 | Oct 20, 2016 | Mar 2027phase 3 · NCT04833894 |
Also a collaborator on its studies: iqvia-pty-ltd, Zai Lab and quintiles-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Oct 20, 2016.
- Apr 26, 2024Phase 3 study in Myasthenia GravisNCT06392386 · 12 planned · United States, Australia, Belgium and more
- Jul 31, 2024Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06544499 · 69 planned · United States, Austria, Bulgaria and more
- Aug 14, 2024Phase 3 study in Myasthenia GravisNCT06558279 · 141 enrolled · United States, Australia, Austria and more
- Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06637072 · 23 enrolled · United States
- Oct 22, 2024Phase 2 study in Scleroderma, SystemicNCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
- Nov 10, 2024Phase 3 study in Primary Sjogrens DiseaseNCT06684847 · 631 enrolled · United States, Argentina, Australia and more
- Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)NCT06909214 · 30 planned · United States
- Sep 19, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07194850 · 24 planned · France, Germany, Italy and more
- Dec 8, 2025Phase 2 study in Myasthenia GravisNCT07284420 · 70 planned · United States, Belgium, Germany and more
- Apr 30, 2026Phase 3 study in Graves DiseaseNCT07570316 · 230 planned · United States, Georgia, United Kingdom
- May 7, 2026Phase 2 study in Autoimmune Diseases of the Nervous SystemNCT07583641 · 170 planned · United States
- May 13, 2026Phase 3 study in Graves DiseaseNCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
- Jul 29, 2026Phase 2 study in Sjogrens DiseaseNCT07760818 · 75 planned
- Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925
Ahead
- Mar 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT06655155
- Mar 2027Primary completion: phase 3 study in Myasthenia GravisNCT04833894
- Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT04280718
- Jul 2027Primary completion: phase 3 study in Primary Sjogrens DiseaseNCT06684847
TargetBeta
“IgG receptor FcRn large subunit p51 antagonist”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rozanolixizumabrule | UCB | phase 4 | 23 |
| nipocalimabrule | Johnson & Johnson | phase 3 | 24 |
| batoclimabrule | immunovant-sciences-gmbh | phase 3 | 18 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07760818Sjogrens Disease | 2 | Not yet recruiting | Jul 28, 2028 | 75 |
| NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more | 3 | Recruiting | Jun 2028 | 230 |
| NCT07583641Autoimmune Diseases of the Nervous System · United States | 2 | Not yet recruiting | Jul 2030 | 170 |
| NCT07570316Graves Disease · United States, Georgia, United Kingdom | 3 | Recruiting | Jun 2028 | 230 |
| NCT07284420Myasthenia Gravis · United States, Belgium, Germany and more | 2 | Recruiting | Mar 7, 2028 | 70 |
| NCT07194850Purpura, Thrombocytopenic, Idiopathic · France, Germany, Italy and more | 3 | Recruiting | Oct 2028 | 24 |
| NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States | 4 | Recruiting | Aug 2026 | 30 |
| NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2027 | 631 |
| NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Mar 2027 | 87 |
| NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States | 4 | Completed | Feb 19, 2026 | 23 |
| NCT06558279Myasthenia Gravis · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 12, 2026 | 141 |
| NCT06544499Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Bulgaria and more | 3 | Recruiting | Jun 2028 | 69 |
| NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | Sep 2027 | 12 |
| NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more | 3 | Terminated | Dec 15, 2025 | 105 |
| NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Terminated | Dec 15, 2025 | 102 |
| NCT06298552Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Active, not recruiting | Jun 30, 2025 | 119 |
| NCT06203457Primary Sjögren's Syndrome · Belgium, Hungary, Poland | 2 | Completed | Feb 3, 2025 | 24 |
| NCT05979441Myositis · United States, Argentina, Austria and more | 3 | By invitation | Sep 2028 | 240 |
| NCT05927415Renal Insufficiency · Germany | 1 | Completed | Jun 12, 2024 | 33 |
| NCT05918978Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome · United States | 2 | Terminated | Aug 15, 2024 | 33 |
| NCT05810961Glomerulonephritis, Membranous · China | 2 | Terminated | Aug 5, 2024 | 8 |
| NCT05817669Primary Sjögren's Syndrome · Belgium, Hungary, Netherlands and more | 2 | Completed | Jan 29, 2024 | 34 |
| NCT05810948Lupus Nephritis · China | 2 | Completed | Jul 2, 2025 | 73 |
| NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Terminated | Mar 20, 2025 | 64 |
| NCT05633407Postural Orthostatic Tachycardia Syndrome · United States | 2 | Completed | Apr 18, 2024 | 53 |
| NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Completed | Sep 13, 2024 | 98 |
| NCT05163834Healthy Volunteers · Netherlands | 1 | Completed | Mar 8, 2022 | 36 |
| NCT04980495Myasthenia Gravis · United States, Austria, Belgium and more | 3 | Completed | Aug 24, 2023 | 69 |
| NCT04833894Myasthenia Gravis · United States, Austria, Belgium and more | 3 | Active, not recruiting | Mar 2027 | 15 |
| NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 2027 | 173 |
| NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more | 3 | Completed | Dec 31, 2024 | 184 |
| NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more | 3 | Completed | Nov 2, 2021 | 110 |
| NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | Oct 9, 2023 | 207 |
| NCT04598477Pemphigus · United States, Australia, Bulgaria and more | 3 | Terminated | Mar 25, 2024 | 183 |
| NCT04598451Pemphigus · United States, Australia, Bulgaria and more | 3 | Completed | Aug 22, 2023 | 222 |
| NCT04564066Healthy Volunteers · Netherlands | 1 | Completed | Dec 24, 2020 | 54 |
| NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more | 2 | Active, not recruiting | Apr 30, 2027 | 229 |
| NCT04274452Purpura, Thrombocytopenic, Idiopathic | 3 | Withdrawn | Sep 1, 2021 | 0 |
| NCT04225156Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Belgium and more | 3 | Completed | Mar 11, 2026 | 101 |
| NCT04188379Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Belgium and more | 3 | Completed | Feb 3, 2022 | 131 |
| NCT04073589Healthy Volunteers · Netherlands | 1 | Completed | Sep 26, 2019 | 33 |
| NCT03770403Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Completed | Jun 23, 2022 | 151 |
| NCT03669588Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Completed | Apr 6, 2020 | 167 |
| NCT03457649Healthy Volunteers | 1 | Completed | Nov 15, 2016 | 62 |
| NCT03334084Bioavailability Study · Netherlands | 1 | Completed | Sep 19, 2018 | 40 |
| NCT03334058Pemphigus · Germany, Hungary, Israel and more | 2 | Completed | Oct 28, 2020 | 34 |
| NCT03102593Purpura, Thrombocytopenic, Idiopathic · Austria, Belgium, Czechia and more | 2 | Completed | Apr 9, 2019 | 38 |
| NCT02965573Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Oct 20, 2017 | 24 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “Efgartigimod IV”, 7 entries
- “ARGX-113”, 7 entries
- “Efgartigimod”, 5 entries
Conditions, from the studies’ own filings
- Myasthenia Gravis, 12 studies
- Purpura, Thrombocytopenic, Idiopathic, 8 studies
- Pemphigus, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Graves Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.